INTRODUCTION
The endocannabinoid system and its role in energy homeostasis and abdominal obesity management During the last two decades, the prevalence of obesity has increased to reach pandemic levels of prevalence. More than one billion people worldwide are now overweight and obesity leads to a marked financial burden on health care systems. Obesity provokes or aggravates several pathologies alone or in combination with other health problems. Obesity, in particular visceral obesity, is associated with development of atherosclerotic cardiovascular disease, type 2 diabetes, hypertension, gallbladder disease, certain forms of cancer and respiratory diseases. According to conservative estimates, the economic costs of obesity range from 2 to 10% of total health care budgets in industrialized countries. There is a tremendous challenge to prevent obesity and to develop effective treatments. The high prevalence of both obesity and its costly comorbidities have significantly contributed to intensify the efforts to understand obesity, which is now at the forefront of biochemical, biomolecular and neurobiological research. Indeed, in the last 20 years, research has generated many important discoveries, which include those of adipose tissue-derived hormones such as leptin and adiponectin, those of the uncoupling proteins two (UCP2) and three (UCP3) and the determination of numerous central and peripheral circuitries involved in energy balance regulation. All these important discoveries were strongly related to the study of body weight regulation, which is central to the understanding of the etiology of obesity. Although obesity research has produced significant results, there are still tremendous efforts to pursue in order to elucidate the mechanisms through which obesity leads to health complications.
It is within the mission of the Merck Frosst/CIHR Research Chair in Obesity (formerly the Donald B Brown Research Chair in Obesity) to provide continuing education about the best possible knowledge on obesity to scientists, physicians, health professionals as well as to the public at large regarding the causes, the complications, the treatment and the prevention of obesity. In this regard, the purpose of the annual symposium is to summarize evidence regarding important topics related to obesity and propose novel obesity research directions. The Merck Frosst/CIHR Research Chair in Obesity has held, so far, five international symposia entirely devoted to obesity research, since its creation in 1997. The first symposium of the series, entitled 'The Uncoupling Proteins and Obesity', was held in 1998 (Int J Obes 23 (Suppl 6), June 1999). The second symposium, which was organized the following year, was oriented towards 'The New Biology of Adipose Tissue' Given the originality and importance of the research currently performed on the endocannabinoid system to unravel the mechanisms whereby energy homeostasis is achieved in order to determine therapeutic targets, an advisory committee to the Chair on the symposium series recommended that the present symposium be organized on that important topic. The scientific program committee for this symposium, which was chaired by D Richard (Canada), included JP Després (Canada), K Sharkey (Canada), V Di
